Benitec Biopharma Announces Director Changes and Officer Compensation Updates
Ticker: BNTC · Form: 8-K · Filed: Jul 1, 2024 · CIK: 1808898
Sentiment: neutral
Topics: director-change, officer-compensation, governance
TL;DR
Benitec Biopharma swapped a director and tweaked exec pay. Board changes are in.
AI Summary
On June 26, 2024, Benitec Biopharma Inc. filed an 8-K report detailing the departure of Director Dr. David J. Wood and the appointment of Dr. Christopher P. De Souza as a new director. The company also announced changes to its compensatory arrangements for certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Director changes and compensation adjustments can indicate internal shifts that may affect the company's strategic direction and operational stability.
Key Players & Entities
- Benitec Biopharma Inc. (company) — Registrant
- Dr. David J. Wood (person) — Departing Director
- Dr. Christopher P. De Souza (person) — Newly Appointed Director
- June 26, 2024 (date) — Date of earliest event reported
FAQ
Who has departed from the Benitec Biopharma Inc. board of directors?
Dr. David J. Wood has departed from the board of directors of Benitec Biopharma Inc.
Who has been appointed as a new director to Benitec Biopharma Inc.'s board?
Dr. Christopher P. De Souza has been appointed as a new director to Benitec Biopharma Inc.'s board.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 26, 2024.
What other items are covered in this 8-K filing besides director changes?
This 8-K filing also covers the election of directors and compensatory arrangements of certain officers.
What is the principal executive office address for Benitec Biopharma Inc.?
The principal executive office address for Benitec Biopharma Inc. is 3940 Trust Way, Hayward, California 94545.
Filing Stats: 777 words · 3 min read · ~3 pages · Grade level 10.6 · Accepted 2024-07-01 16:30:30
Key Financial Figures
- $0.0001 B — ich registered Common Stock, par value $0.0001 BNTC The Nasdaq Stock Market LLC Indic
Filing Documents
- d853226d8k.htm (8-K) — 27KB
- d853226dex991.htm (EX-99.1) — 10KB
- g853226benitec.jpg (GRAPHIC) — 11KB
- 0001193125-24-173338.txt ( ) — 174KB
- bntc-20240626.xsd (EX-101.SCH) — 3KB
- bntc-20240626_lab.xml (EX-101.LAB) — 17KB
- bntc-20240626_pre.xml (EX-101.PRE) — 11KB
- d853226d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Board Designation Agreement, dated April 22, 2024, by and between Benitec Biopharma Inc. and Suvretta Capital Management, LLC (incorporated by reference to Exhibit 10.4 to the Company's Quarter Report on Form 10-Q filed on May 13, 2024) 99.1 Press Release dated July 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: July 1, 2024 By: /s/ Dr. Jerel A. Banks Name: Dr. Jerel A. Banks Title: Chief Executive Officer